Tracy Nelson
Family · Milwaukee, WINPI 1346499738
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 59.6% of the total. Reporting peaked in 2021 at $11,988 and has fallen 85.1% since, to $1,792 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $45.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$15K
- UCB, Inc.$4K
- AbbVie$1K
- Sanofi$698
- Johnson & Johnson$661
- Arcutis Biotherapeutics, Inc.$431
- plus $2K from 18 others
What the payments were for
- Consulting fees$1,5006%
- Speaking & faculty fees$13,43355%
- Travel & lodging$7933%
- Food & beverage$7,85532%
- Education$8984%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 219 | $14,579 |
| UCB, Inc. | 33 | $4,406 |
| AbbVie | 122 | $1,382 |
| Sanofi | 28 | $698 |
| Johnson & Johnson | 23 | $661 |
| Arcutis Biotherapeutics, Inc. | 17 | $431 |
| Sanofi-aventis U.S. LLC | 5 | $361 |
| Incyte Corporation | 6 | $347 |
| Lilly USA, LLC | 17 | $343 |
| E.r. Squibb & Sons, L.L.C. | 12 | $281 |
| Novartis | 12 | $229 |
| Amgen | 10 | $169 |
| Pfizer | 9 | $140 |
| Janssen Scientific Affairs, LLC | 1 | $102 |
| LEO Pharma Inc. | 4 | $72 |
| Galderma Laboratories, L.p. | 3 | $54 |
| Mayne Pharma Commercial LLC | 2 | $52 |
| Organon | 4 | $45 |
| Biosense Webster, Inc. | 1 | $36 |
| Biofrontera Inc. | 2 | $24 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Dermavant Sciences, Inc. | 1 | $17 |
| Botanix SB Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,480 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 80 | $316,079 |
| Skyrizi PenRisankizumab-Rzaa | 15 | $314,445 |
| OtezlaApremilast | 48 | $247,195 |
| StelaraUstekinumab | 11 | $242,712 |
| TremfyaGuselkumab | 11 | $146,782 |
| Enbrel MiniEtanercept | 12 | $93,725 |
| Dupixent SyringeDupilumab | 21 | $82,124 |
| VtamaTapinarof | 12 | $18,202 |
| Ketoconazole | 180 | $3,555 |
| Clobetasol Propionate | 73 | $2,545 |
| Triamcinolone Acetonide | 182 | $2,350 |
| Metronidazole | 34 | $2,312 |
| Tretinoin | 17 | $1,950 |
| Tacrolimus | 11 | $1,701 |
| Fluocinonide | 17 | $992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Tremfya | $661 | $389,49422 claims |
| AmgenOtezla | $169 | $247,19548 claims |
| Dermavant Sciences, Inc.Vtama | $17 | $18,20212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.
Other family in Milwaukee
- Stephanie OffordMilwaukee$116K
- Sarah EmmerichMilwaukee$15K
- Erin LassanskeMilwaukee$14K
- Katrina BaxterMilwaukee$13K
- Natalie KerberMilwaukee$12K
- Jenta AlexanderMilwaukee$12K
- Lileta WintMilwaukee$10K
- Mary Jane de JesusMilwaukee$10K
- Kelley BeltranMilwaukee$9K
- Angela GillMilwaukee$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.